Market Closed -
OTC Markets
07:35:38 25/06/2024 pm IST
5-day change
1st Jan Change
0.0001
USD
0.00%
0.00%
-98.04%
Inspyr Therapeutics, Inc. Announces Resignation of Russell Richerson as Chief Operating Officer
March 04, 2017 at 03:19 am IST
On February 28, 2017, Russell Richerson, PhD, resigned as chief operating officer of the Inspyr Therapeutics, Inc., effective immediately.
Rebus Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
22/23/22
CI
Rebus Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
16/23/16
CI
Rebus Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
01/23/01
CI
Rebus Holdings, Inc. Auditor Raises 'Going Concern' Doubt
31/23/31
CI
Rebus Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
22/22/22
CI
Rebus Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
12/22/12
CI
Rebus Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
14/22/14
CI
Rebus Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
01/22/01
CI
Rebus Holdings, Inc. Auditor Raises 'Going Concern' Doubt
31/22/31
CI
Rebus Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
13/21/13
CI
Inspyr Therapeutics Announces New Holding Company Structure
12/21/12
CI
Inspyr Therapeutics, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2021
17/21/17
CI
Inspyr Therapeutics, Inc. Announces Resignation of Michael Cain as Chief Executive Officer
21/21/21
CI
Inspyr Therapeutics, Inc. announced that it has received $0.6 million in funding
18/21/18
CI
Inspyr Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021
18/21/18
CI
Inspyr Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020
01/21/01
CI
Inspyr Therapeutics, Inc. announced that it has received $0.5 million in funding
12/21/12
CI
Inspyr Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
21/20/21
CI
Inspyr Therapeutics, Inc. announced that it has received $0.5 million in funding
23/20/23
CI
Inspyr Therapeutics, Inc. Enters into Termination of License Agreement with Ridgeway Therapeutics, Inc
09/20/09
CI
Inspyr Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020
15/20/15
CI
Inspyr Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020
07/20/07
CI
Inspyr Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019
15/20/15
CI
Inspyr Therapeutics, Inc. announced that it has received $0.25 million in funding
06/20/06
CI
Inspyr Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
21/19/21
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Rebus Holdings, Inc. is a pharmaceutical company. The Company is focused on the research and development of targeted precision therapeutics for the treatment of cancer. The Company utilizes its proprietary delivery technology to enhance immuno-modulation for developing therapeutic outcomes. Its immune-oncology lead asset, RT-AR001, is an adenosine A2A receptor antagonist, is differentiated by its intratumoral delivery of nano- or microparticle formulations that allow for better tumor infiltration. Its patented portfolio of adenosine receptor antagonists provides treatment based on the specific adenosine targets found in each type of cancer. The adenosine receptor modulators include A2A, A2B and dual A2A/A2B antagonists, that have broad development applicability, including indications within immuno-oncology. It is also engaged in the manufacturing of platform delivery systems for nano- or microparticle formulations that are used in toxicology studies.
More about the company
1st Jan change
Capi.
-98.04% 3.21T +16.45% 12TCr +21.96% 11TCr +23.73% 2.59TCr -20.05% 2.09TCr -16.28% 1.68TCr -16.52% 1.65TCr -44.35% 1.56TCr +63.91% 1.55TCr +2.52% 1.34TCr
Bio Therapeutic Drugs
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
REBUS HOLDINGS, INC. 
